Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine

Podzamczer, Daniel; Ferrer, Elena; Sanchez, Pochita; M. Gatell, José; Crespo, Manel; Fisac, Cesar; Loncà, Montse; Sanz, José; Niubó, Jordí; Veloso, Sergio; M. Llibre, Josep; Barrufet, Pilar; A Ribas, María; Merino, Esperanza; Ribera, Esteban; Martínez-Lacasa, Javier; Agustín Isidro Alonso, Carlos; Aranda, Miquel; Pulido, Federico; Berenguer, Juan; Delegido, Antonio; D Pedreira, Juan; Lérida, Ana; Rubio, Rafael; del Río, Luis

doi:10.1097/qai.0b013e31802bf122

Public

Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine

Published in JAIDS Journal of Acquired Immune Deficiency Syndromes • Nov 22, 2006

Authors:

Daniel Podzamczer

Elena Ferrer

Pochita Sanchez

Abstract

OBJECTIVE: To assess lipoatrophy, other toxicities, and efficacy associated with abacavir as compared with stavudine in HIV-infected antiretroviral-naive patients. METHODS: This was a prospective, randomized, open trial, stratified by viral load and CD4 cell count, conducted January 2001 to July 200...

Subject

Stavudine

Lipoatrophy

Abacavir

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!